Company intelligence / Profile preview

Hemofarm

Vršac, Serbia

Ownership: Private
Employees: ~3134
Development stage: Other

Overview

Hemofarm is a leading pharmaceutical company in Serbia and the regional market, specializing in the manufacture of generic Rx and OTC medicines. With a portfolio exceeding 140 International Nonproprietary Names (INNs), it operates in over 30 countries. It serves as a competence center for the development of new generic products for STADA Group. As a generics manufacturer, it does not develop innovative drugs and therefore does not have a traditional clinical pipeline of new molecular entities or associated clinical results.

Modalities: Small moleculeBiologic
Industry: Contract Manufacturing Organization

Partnerships

STADA Group

Beyond the preview

Go deeper on Hemofarm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemofarm.

Explore the full profile